Abstract
Stent thrombosis (ST) is a rare complication following coronary stenting; however given the associated serious consequences, in particular death and myocardial infarction, it remains a source of considerable concern for cardiologists. Although no differences have been found between drug-eluting stents (DES) and bare-metal stents (BMS) in terms of early ST, some studies have reported adverse outcomes associated with DES as compared to BMS at long-term follow-up. Delayed endothelial coverage of the stent struts, inflammation and local hypersensitivity due to the interaction between the drug and polymer coating have been characterized to be typical for DES compared to BMS and may prolong the window of vulnerability to ST. Consequently the recommended duration of dual antiplatelet therapy (DAT) was longer with DES than with BMS. Results from studies investigating the optimal duration of DAT remain inconclusive and the current recommendation seems to be that patients undergoing DES implantation should have DAT for at least 6-12 months. Our treatment strategy requires more detailed analysis and should improve as we understand more about the impact of the newer generation DES and variability in antiplatelet therapy response, in addition to the effects of novel therapeutic agents and the availability of more data on the optimum duration of DAT.
Keywords: Coronary, angioplasty, drug-eluting stent, thrombosis, antiplatelet therapy, Stent Thrombosis, myocardial infarction, drug-eluting stents, cardiologists, bare-metal stents, restenosis, Gianturco-Roubin stent, aspirin, thienopyridine, ticlopidine, clopidogrel, sirolimus-eluting stent, myocardial, Basel Stent Kosten Effektivitäts, endothelialization, everolimus-eluting stent, phosphorylcholine, polivynilpyrrolidone, rapamycin-eluting stents, Biolimus-eluting stent, intra-vascular ultrasound, optical coherence tomography, MACE, SIRIUS trials, neointimal/plaque rupture, malapposition, acute coronary syndrome, light transmittance aggregometry
Current Pharmaceutical Design
Title: Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Volume: 16 Issue: 36
Author(s): Alfonso Ielasi, Rasha Al-Lamee and Antonio Colombo
Affiliation:
Keywords: Coronary, angioplasty, drug-eluting stent, thrombosis, antiplatelet therapy, Stent Thrombosis, myocardial infarction, drug-eluting stents, cardiologists, bare-metal stents, restenosis, Gianturco-Roubin stent, aspirin, thienopyridine, ticlopidine, clopidogrel, sirolimus-eluting stent, myocardial, Basel Stent Kosten Effektivitäts, endothelialization, everolimus-eluting stent, phosphorylcholine, polivynilpyrrolidone, rapamycin-eluting stents, Biolimus-eluting stent, intra-vascular ultrasound, optical coherence tomography, MACE, SIRIUS trials, neointimal/plaque rupture, malapposition, acute coronary syndrome, light transmittance aggregometry
Abstract: Stent thrombosis (ST) is a rare complication following coronary stenting; however given the associated serious consequences, in particular death and myocardial infarction, it remains a source of considerable concern for cardiologists. Although no differences have been found between drug-eluting stents (DES) and bare-metal stents (BMS) in terms of early ST, some studies have reported adverse outcomes associated with DES as compared to BMS at long-term follow-up. Delayed endothelial coverage of the stent struts, inflammation and local hypersensitivity due to the interaction between the drug and polymer coating have been characterized to be typical for DES compared to BMS and may prolong the window of vulnerability to ST. Consequently the recommended duration of dual antiplatelet therapy (DAT) was longer with DES than with BMS. Results from studies investigating the optimal duration of DAT remain inconclusive and the current recommendation seems to be that patients undergoing DES implantation should have DAT for at least 6-12 months. Our treatment strategy requires more detailed analysis and should improve as we understand more about the impact of the newer generation DES and variability in antiplatelet therapy response, in addition to the effects of novel therapeutic agents and the availability of more data on the optimum duration of DAT.
Export Options
About this article
Cite this article as:
Ielasi Alfonso, Al-Lamee Rasha and Colombo Antonio, Stent Thrombosis and Duration of Dual Antiplatelet Therapy, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454851
DOI https://dx.doi.org/10.2174/138161210794454851 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Renal Function, Albumin-Creatinine Ratio and Pulse Wave Velocity Predict Silent Coronary Artery Disease and Renal Outcome in Type 2 Diabetic and Prediabetic Subjects
Current Hypertension Reviews An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Radix Paeoniae Rubra Ameliorates Lupus Nephritis in Lupus-Like Symptoms of Mrl Mice by Reducing Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and Platelet Endothelial Cell Adhesion Molecule-1 Expression
Combinatorial Chemistry & High Throughput Screening Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)